GeneSight Testing FDA Approval Status
GeneSight is not FDA-approved as a complete diagnostic test, but operates as a laboratory-developed test (LDT) under CLIA certification, with only certain individual gene components having FDA clearance.
Regulatory Classification
GeneSight functions as a laboratory-developed test (LDT), which means it is:
- Developed, manufactured, and used within a single laboratory
- Subject to CLIA (Clinical Laboratory Improvement Amendments) regulations rather than full FDA approval 1, 2
- Not required to undergo the FDA's premarket approval (PMA) or 510(k) clearance process that applies to commercially distributed diagnostic kits
The FDA has historically exercised "enforcement discretion" toward LDTs, meaning they have authority to regulate these tests but have largely chosen not to do so 1.
What This Means Clinically
CLIA certification ensures laboratory quality standards but does not evaluate:
- Clinical validity (how accurately the test predicts clinical outcomes)
- Clinical utility (whether the test improves patient outcomes) 3, 1
The distinction is critical: CLIA regulates the laboratory's quality processes, while FDA approval would evaluate whether the test itself is safe and effective 1.
FDA-Cleared Components vs. Complete Test
Some individual genetic markers tested by GeneSight may use FDA-cleared platforms or reagents (such as tests for CYP2D6, CYP2C19, and CYP2C9 genes mentioned in NCCN guidelines 3). However, the complete GeneSight panel—including its proprietary algorithms, gene combinations, and clinical decision support—has not undergone FDA approval as an integrated diagnostic device.
Clinical Evidence Considerations
Recent research shows:
- GeneSight-guided care demonstrated improved response (RR 1.30) and remission (RR 1.53) in major depressive disorder in platform-specific RCT analysis 4
- Evidence quality remains low to very low by GRADE criteria 5
- Real-world studies show 94.5% of tested individuals have actionable variants, but EHR integration remains inconsistent 6
Common Pitfalls
Do not assume CLIA certification equals FDA approval—these are fundamentally different regulatory pathways with different standards. CLIA ensures the laboratory can perform the test reliably; FDA approval would confirm the test improves clinical outcomes.
Insurance coverage varies significantly because payors often require demonstration of clinical utility beyond what CLIA certification provides 3, 1.